Showing results (251-260 of 316) with videos related to
Sort By:
Pageof 32
Revista Espanola De Enfermedades Digestivas|October 29, 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)Javier Crespo, Albillos Albillos, María Buti, et al.Hepatology (Baltimore, Md.)|April 8, 2022
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemiaMarta Alonso-Peña, Ricardo Espinosa-Escudero, Elisa Herraez, et al.Gastroenterologia Y Hepatologia|October 10, 2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)Javier Crespo, Agustín Albillos, María Buti, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 4, 2025
Defining non-invasive criteria for indicating drug therapy in metabolic-associated steatotic liver disease in clinical practiceAntonio Olveira, Javier Crespo, Luis Ibañez-Samaniego, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2017
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 InfectionJavier Crespo, Jose Luis Calleja, Inmaculada Fernández, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 16, 2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisJörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, et al.Alimentary Pharmacology & Therapeutics|April 26, 2022
Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter studyLuis Téllez, Eugenia Sánchez Rodríguez, Enrique Rodríguez de Santiago, et al.Nature Communications|July 5, 2020
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidationLucía Barbier-Torres, Karen A Fortner, Paula Iruzubieta, et al.Journal of Hepatology|December 31, 2017
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis CJavier Ampuero, Carlota Jimeno, Rosa Quiles, et al.Hepatology (Baltimore, Md.)|January 10, 2023
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administrationÁlvaro Díaz-González, Manuel Hernández-Guerra, Indhira Pérez-Medrano, et al.Pageof 32